Insider Trading April 14, 2026 04:16 PM

Aehr Test Systems CEO Disposes of $10.7M in Shares as Stock Nears Yearly High

Gayn Erickson sells majority of April stake while company posts mixed Q3 fiscal 2026 results and strong bookings

By Maya Rios AEHR
Aehr Test Systems CEO Disposes of $10.7M in Shares as Stock Nears Yearly High
AEHR

Gayn Erickson, president and chief executive of Aehr Test Systems (NASDAQ: AEHR), sold 152,824 shares on April 10, 2026, for roughly $10.7 million as the stock traded close to its 52-week peak. He also sold an additional 3,704 shares on April 11 to satisfy tax liabilities. The company reported mixed third-quarter fiscal 2026 financials, with EPS beating expectations but revenue falling short, even as bookings reached a record level and backlog topped $50 million.

Key Points

  • Aehr Test Systems CEO Gayn Erickson sold 152,824 shares on April 10, 2026, for about $10.7 million at $70.5831 per share and sold 3,704 shares on April 11, 2026, at $70.43 to cover taxes, totaling $260,872.
  • After the transactions, Erickson directly owns 191,999 shares (including unvested restricted stock units and restricted shares) and indirectly holds 197,723 shares in trust; the sales were reported by his attorney-in-fact, Chris Siu.
  • Aehr Test Systems reported mixed Q3 fiscal 2026 results: EPS of -$0.05 beat estimates of -$0.07, revenue of $10.3 million missed expectations of $10.8 million, while bookings reached a record $37.2 million and backlog exceeded $50 million; analysts adjusted price targets in response.

Lead

Gayn Erickson, the president and chief executive officer of Aehr Test Systems (NASDAQ: AEHR), executed a large sale of company stock in April 2026 while the shares were trading near their 52-week high.


Insider transactions

According to a Form 4 filing with the Securities and Exchange Commission, Erickson sold 152,824 shares of common stock on April 10, 2026, at a per-share price of $70.5831, generating approximately $10.7 million in proceeds. The filing further shows that on April 11, 2026, he disposed of 3,704 additional shares to cover tax obligations; that transaction occurred at $70.43 per share and totaled $260,872.

The sale filings were submitted through Erickson's attorney-in-fact, Chris Siu.


Post-sale holdings

After these transactions, Erickson is reported to directly own 191,999 shares of Aehr Test Systems. That reported total includes shares that remain subject to unvested restricted stock units and unvested restricted shares. In addition to his direct holdings, he indirectly holds 197,723 shares in a trust.


Share performance context

The insider sales came as Aehr Test Systems' shares were trading close to a 52-week high of $74.53, following an extraordinary 763% increase in the prior 12 months.


Company financials and demand indicators

In other filings and disclosures, Aehr Test Systems reported mixed third-quarter results for fiscal 2026. The company recorded diluted earnings per share of -$0.05, outperforming analysts' consensus of -$0.07. Revenue for the quarter was $10.3 million, short of the $10.8 million that analysts had expected.

Offsetting the revenue shortfall, Aehr Test Systems posted record quarterly bookings of $37.2 million and said its backlog exceeded $50 million. Analysts cited the company's strong bookings momentum and an elevated book-to-bill ratio as important demand signals.


Analyst adjustments

Following the results and bookings update, Freedom Broker raised its price target on Aehr Test Systems from $38.00 to $61.00 while maintaining a Hold rating. Lake Street also lifted its target, increasing it to $56 from $50, and referenced the robust bookings and a book-to-bill ratio above 3.5x.


Takeaway

The April insider sales, disclosed via Form 4 filings, occurred against a backdrop of mixed quarterly operating results but strong near-term demand indicators for Aehr Test Systems. Erickson's reported holdings now comprise both direct and indirect positions, some of which include unvested restricted shares.

Risks

  • The company reported lower-than-expected revenue for Q3 fiscal 2026, which may create near-term pressure on top-line performance - relevant to investors in semiconductors and testing equipment sectors.
  • Insider selling while the stock trades near its 52-week high introduces uncertainty about near-term insider conviction, which could influence market sentiment in the stock and related small-cap technology names.
  • Although bookings were strong, reliance on a booked backlog introduces execution and timing risk for revenue recognition, affecting revenue-sensitive stakeholders and equipment suppliers.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026